Moderna doses first patients across four new Phase I clinical studies
Category: #health  By Pankaj Singh  Date: 2019-08-09
  • share
  • Twitter
  • Facebook
  • LinkedIn

Moderna doses first patients across four new Phase I clinical studies

Moderna, a biotech company that focuses on discovery and development of drugs and is based in Cambridge, Massachusetts, announced recently that it has initiated four new Phase I clinical trials, two of which are related to infectious diseases and two in immuno-oncology.

Additionally, in a Phase II study regarding a vaccine for melanoma, first patient has given consent for continuing with the trial. This announcement was made along with the second quarter of 2019 earnings of the company.

Apparently, Moderna’s share rose up by 14% on Nasdaq after the news was announced. The company raised over $600 million after it made its debut in stock market in November 2018, and  the largest initial public offering that was ever made by a biotech company.

According to reports, the company had dosed its first patient in the mRNA-1172’s Phase I study, which is a vaccine made for respiratory syncytial virus (RSV) as well as in mRNA-1893 trial, another vaccine made for Zika virus. For immune-oncology, the company reportedly dozed first patients in the trial for KRAS vaccine for cancer mRNA-5671’S and also a therapy for mRNA-encoding IL12.

Moderna has been developing the KRAS cancer vaccine and the RSV vaccine in partnership with Merck & Co., whereas under the partnership with MedImmune, subsidiary of AstraZeneca, a British drug maker, the company was developing IL12, under the name MEDI1191.

Patients suffering from number of solid tumors together are being co-administered with MEDI1191 with PD-L1 checkpoint inhibitor, AstraZeneca Imfinzi. Drug makers have been taking keen interest in the in the areas of developing KRAS protein for its wide expression in multiple solid tumors, and is considered undruggable owing to its structure.

Reportedly, Amgen has been in the process of developing AMG 510, that targets KRAS G12C, a form of KRAS that has shown efficacy in various patients. Various startups have been involved in the investigation of product candidates that also target KRAS mutations.

 

Source Credit- https://medcitynews.com/2019/08/moderna-builds-up-clinical-pipeline-as-multiple-new-drugs-enter-phase-i-testing/?rf=1



About Author

Pankaj Singh

Email: [email protected]   

Pankaj Singh

Pankaj Singh Develops content for Market Size Forecasters, Algosonline, and a couple of other platforms. A Post Graduate in Management by qualification, he worked as an underwriter in the UK insurance domain before deciding to switch his field of profession. With exp...

Read More

More News By Pankaj Singh

Amazon cleared by UK regulators to buy 16% stake in Deliveroo
Amazon cleared by UK regulators to buy 16% stake in Deliveroo
By Pankaj Singh

The eCommerce giant Amazon has been granted permission to purchase a minority stake in the U.K-based food delivery start-up Deliveroo. The firm was able to convince regulators that the deal would not be detrimental to ...

Australia retail industry in disarray with major slump in sales
Australia retail industry in disarray with major slump in sales
By Pankaj Singh

Australia’s retailers are reportedly facing a huge crisis of sorts, with the latest data depicting a massive fall in sales volumes. As the nation’s second-largest state enforces a lockdown to fight the ongo...

Leedy Dental Reveals Renovations and New Dental Implant Center
Leedy Dental Reveals Renovations and New Dental Implant Center
By Pankaj Singh

The Leedy Dental, the U.S-based comprehensive dental practice with expertise in full mouth rehabilitation and implant dentistry, has reportedly completed renovation work in its practice in Abilene, TX.  

...